Kenneth Tew to Prostatic Neoplasms
This is a "connection" page, showing publications Kenneth Tew has written about Prostatic Neoplasms.
Connection Strength
1.403
-
S-Glutathionylated Serine Proteinase Inhibitors as Biomarkers for Radiation Exposure in Prostate Cancer Patients. Sci Rep. 2019 09 24; 9(1):13792.
Score: 0.424
-
ABCA2 transporter deficiency reduces incidence of TRAMP prostate tumor metastasis and cellular chemotactic migration. Cancer Lett. 2011 Jan 28; 300(2):154-61.
Score: 0.229
-
Evaluation of lipophilins as determinants of tumor cell response to estramustine. J Pharmacol Exp Ther. 2005 Dec; 315(3):1158-62.
Score: 0.160
-
Interaction of an estramustine photoaffinity analogue with cytoskeletal proteins in prostate carcinoma cells. Mol Pharmacol. 1994 Nov; 46(5):866-72.
Score: 0.075
-
Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines. Cancer Res. 1992 Aug 15; 52(16):4433-40.
Score: 0.065
-
Resistance to the antimitotic drug estramustine is distinct from the multidrug resistant phenotype. Br J Cancer. 1991 Aug; 64(2):267-73.
Score: 0.060
-
The effects of estramustine on metaphase and anaphase in DU 145 prostatic carcinoma cells. Eur J Cell Biol. 1991 Apr; 54(2):268-76.
Score: 0.059
-
Mechanism based chemotherapy for prostate cancer. Cancer Surv. 1991; 11:239-54.
Score: 0.058
-
Dansylated estramustine, a fluorescent probe for studies of estramustine uptake and identification of intracellular targets. Proc Natl Acad Sci U S A. 1985 Dec; 82(24):8483-7.
Score: 0.041
-
Antimicrotubule effects of estramustine, an antiprostatic tumor drug. Cancer Res. 1985 Aug; 45(8):3891-7.
Score: 0.040
-
Identification of a novel first exon of the human ABCA2 transporter gene encoding a unique N-terminus. Biochim Biophys Acta. 2004 Apr 16; 1678(1):22-32.
Score: 0.036
-
Estramustine resistance correlates with tau over-expression in human prostatic carcinoma cells. Int J Cancer. 1998 Aug 12; 77(4):626-31.
Score: 0.025
-
Association of estramustine resistance in human prostatic carcinoma cells with modified patterns of tubulin expression. Biochem Pharmacol. 1998 Feb 01; 55(3):325-31.
Score: 0.024
-
Interaction of estramustine with tubulin isotypes. Biochemistry. 1997 Jan 28; 36(4):871-8.
Score: 0.022
-
Increase of beta(III)- and beta(IVa)-tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance. Cancer Res. 1996 Jun 01; 56(11):2584-9.
Score: 0.021
-
Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J Clin Oncol. 1992 Nov; 10(11):1754-61.
Score: 0.016
-
Intracellular effects of estramustine (Estracyt/Emcyt). Prog Clin Biol Res. 1989; 303:169-75.
Score: 0.013
-
Hormone-independent, non-alkylating mechanism of cytotoxicity for estramustine. Urol Res. 1987; 15(3):155-60.
Score: 0.011
-
Relationship of glutathione depletion and inhibition of glutathione-S-transferase activity to the antimitotic properties of estramustine. Cancer Treat Rep. 1986 Jun; 70(6):715-20.
Score: 0.011
-
Cytotoxic properties of estramustine unrelated to alkylating and steroid constituents. Urology. 1984 Jun; 23(6 Suppl):28-33.
Score: 0.009
-
Estramustine binds a MAP-1-like protein to inhibit microtubule assembly in vitro and disrupt microtubule organization in DU 145 cells. J Cell Biol. 1988 Dec; 107(6 Pt 2):2647-56.
Score: 0.003
-
Immunofluorescent studies of the anti-microtubule effects of the anti-cancer drug estramustine. Anticancer Res. 1987 Nov-Dec; 7(6):1165-71.
Score: 0.003